Sells PYLARIFY, a PET imaging agent for prostate cancer, alongside diagnostic imaging products and microbubbles to hospitals, imaging centers and government facilities.
10-K for FY2025, filed Feb 26, 2026Year Ended December 31, (in thousands) 2025 2024 2023 PYLARIFY $ 989,116 $ 1,057,834 $ 851,303 Other radiopharmaceutical oncology — 384…View ↗
PYLARIFY (also known as piflufolastat F-18, 18F-DCFPyL or PyL), an F-18-labeled PET imaging agent targeting PSMA used with PET/computed…View ↗
We produce and market our products throughout the United States (the “United States” or the “U.S.”), selling primarily to hospitals…View ↗
DEFINITY, an injectable ultrasound enhancing agent with perflutren-containing lipid microspheres, or microbubbles, which is used in…View ↗
U.S. customers are mainly hospitals, imaging centers and government facilities, alongside other medical buyers. Outside the U.S., Lantheus sells directly in some markets, through third-party distributors in others, and licenses rights to develop and commercialize certain products.
10-K for FY2025, filed Feb 26, 2026We produce and market our products throughout the United States (the “United States” or the “U.S.”), selling primarily to hospitals…View ↗
The Company sells its products principally to hospitals, independent diagnostic testing facilities, and radiopharmacies. The Company…View ↗
We produce and market our products throughout the United States (the “United States” or the “U.S.”), selling primarily to hospitals…View ↗
Yes. It kept 15 cents of every revenue dollar as net income in FY2025 and turned 23 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Nov 5, 2026
In addition, and as previously announced, Lantheus entered into a definitive agreement on August 3, 2026 to merge with Curium under which…View ↗
8-K, filed Oct 22, 2026
On October 21, 2026, the Company and Parent each received a request for additional information and documentary materials (each, a “Second…View ↗
8-K, filed Aug 4, 2026
Upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time”)…View ↗
Sale of SPECT business
The earlier report listed SPECT products including TechneLite, NEUROLITE, Xenon and CARDIOLITE; the latest says the company sold its SPECT business and associated products to SHINE.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026
AZEDRA production ended
The earlier report included AZEDRA as a commercial cancer treatment; the latest says production has been discontinued.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026PYLARIFY (also known as piflufolastat F 18, 18F-DCFPyL or PyL) is an F 18-labelled PSMA-targeted PET imaging agent used with PET/computed…View ↗
The Company classifies its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic…View ↗
RELISTOR royalty rights sold
The earlier report says Lantheus collected quarterly royalties for RELISTOR; the latest says it sold those royalty rights and retained rights to future sales-based milestone payments.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026RELISTOR (methylnaltrexone bromide) is a treatment for opioid-induced constipation (“OIC”) that decreases the constipating side effects…View ↗
Our Strategic Partnerships and Other Revenue, also includes revenue derived from partnerships with pharmaceutical companies and academic…View ↗
Competes with Telix Pharmaceuticals, Blue Earth Diagnostics, Novartis, GE Healthcare, Bracco, Lilly, ITM Radiopharma, Curium, and RayzeBio
10-K for FY2025, filed Feb 26, 2026For PYLARIFY, our principal competitors are currently Telix Pharmaceuticals Limited, Blue Earth Diagnostics Ltd., a subsidiary of Bracco…View ↗
Loading...